Tofacitinib Dosing and Monitoring in Renal Impairment

Dose Adjustment and Monitoring Requirements

For patients with severe renal impairment, the American College of Rheumatology recommends reducing tofacitinib to 5 mg once daily; for moderate impairment, no dose adjustment is required but monitor more closely for infections and cytopenias 1, 2
The European League Against Rheumatism suggests that for mild renal impairment, no dose adjustment is required, but monitoring is essential 3, 1
In moderate renal impairment, enhanced monitoring is crucial, including checking complete blood count, liver enzymes, and renal function at 1 month, 3 months, then every 3 months 1, 4
For patients with end-stage renal disease on hemodialysis, reduce dose to 5 mg once daily 3, 2

Tofacitinib clearance is approximately 70% hepatic and 30% renal excretion of parent drug, and renal impairment substantially increases drug exposure 1, 4

The American College of Rheumatology recommends baseline laboratory monitoring, including complete blood count with differential, liver enzymes, creatinine, and lipid panel 3, 1, 4
Follow-up monitoring should include rechecking at 1 month, 3 months, then every 3 months 1, 4, 2

Patients with renal impairment have higher baseline infection risk, compounded by immunosuppression from tofacitinib, and urinary tract infections are the most common serious infections 2, 5
The European Medicines Agency restricts tofacitinib use in patients >65 years due to increased serious infection risk 7
Carefully evaluate venous thromboembolism risk factors before initiation, particularly in elderly patients with renal impairment 7, 6, 4